Business Wire

Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study

Share

Regulators in three countries have granted approvals to Impella surgical products, as Abiomed (NASDAQ: ABMD) continues to execute its strategy for sustainable growth with new products, new indications and new geographies. In the United States, the Food and Drug Administration (FDA) has granted an Early Feasibility Study (EFS) Investigational Device Exemption (IDE) to Impella BTR (Bridge-to-Recovery). In Asia, Impella 5.5 with SmartAssist has received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and Hong Kong’s Medical Device Division (MDD).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005312/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Impella 5.5 with SmartAssist is now approved for use in Japan and Hong Kong. (Graphic: Business Wire)

Impella 5.5 with SmartAssist is a game-changing technology for patients in Japan and Hong Kong. It is a minimally invasive, forward flow, fully unloading heart pump designed by and for heart surgeons with direct or axillary insertion. It received FDA post-market approval (PMA) two years ago. Since then, it has been used to treat more than 4,000 US patients for indications that include AMI cardiogenic shock, cardiomyopathy and post-cardiotomy cardiogenic shock. Historically, the cardiogenic shock survival rate has been approximately 50%. Impella 5.5 with SmartAssist patients have a 74% survival to explant, with 59% of surviving patients achieving native heart recovery.

In Japan, Impella 5.5 with SmartAssist is now indicated for use in the treatment of drug-resistant acute heart failure attributable to causes such as cardiogenic shock. The first Impella 5.5 with SmartAssist patient in Japan is expected to be treated in the coming months.

“The Japanese market is ideal for Impella 5.5 with SmartAssist because the technology provides minimally invasive, longer-term unloading support, enabling native heart recovery in a country that is more resistant to invasive sternotomies and heart transplants,” said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer.

In the United States, the FDA has approved the Impella BTR early feasibility IDE study, clearing the way for the first patient in the world to be treated with Impella BTR. Impella BTR is a percutaneous heart pump, with greater than six liters of blood flow per minute. It is designed to be much less invasive than current LVADs.

The vision of the Impella BTR development program is to provide a patient with home discharge and up to one year of full hemodynamic support. In the early feasibility study, ten patients will be enrolled at up to five hospitals and supported by Impella BTR for up to 28 days. The first Impella BTR patient is expected to be treated in March or April this year.

“The FDA’s approval is a first step toward making this longer-term minimally invasive forward flow smart heart pump a reality for patients with chronic heart failure,” said Minogue.

Impella BTR is an investigational device, limited by federal law to investigational use only.

ABOUT IMPELLA HEART PUMPS

The Impella 2.5® and Impella CP® devices are US FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.

Impella 2.5, Impella CP, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are US FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.

Impella BTR® is an investigational device, limited by federal law to investigational use only.

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information please contact:

Media Contact:
Tom Langford
Director of Communications
+1 (978) 882-8408
tlangford@abiomed.com

Investor Contact:
Todd Trapp
Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enviva Announces Public Offering of Common Stock20.1.2022 00:38:00 EET | Press release

Enviva Inc. (NYSE: EVA) (“Enviva,” “we,” “us,” or “our”) today announced that it has commenced an underwritten public offering (the “Offering”) of 4,300,000 common shares. Enviva expects to grant the underwriters an option to purchase up to an additional 645,000 common shares from Enviva at the issue price of the Offering. Enviva intends to use the net proceeds of the Offering for general corporate purposes, including pre-funding a portion of its capital expenditures related to ongoing development projects, and the temporary repayment of debt. Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Barclays Capital Inc., BMO Capital Markets Corp., HSBC Securities (USA) Inc., RBC Capital Markets, LLC, and Truist Securities are acting as joint book-running managers for the Offering. Loop Capital Markets LLC, Raymond James & Associates, Inc., and USCA Securities LLC are acting as co-managers for the Offering. The Offering is being made pursuant to an effective

Enviva Announces MOU With U.S. Customer, Provides Updates to Business and Sales Pipeline, and Accelerates Capacity Expansions20.1.2022 00:33:00 EET | Press release

Enviva Inc. (NYSE: EVA) (“Enviva,” “we,” “us,” or “our”) today provided a business update announcing a memorandum of understanding (“MOU”) with Enviva’s first U.S.-based customer, and detailing plans to significantly accelerate its capital expansion timeline due to recent commercial momentum with power and heat generators and with industrials in hard-to-abate sectors. The business update also included preliminary 2021 financial results. Highlights: Announced plans to accelerate doubling of production capacity over the next five years, including bringing forward plans for a third plant in the Pascagoula, Mississippi cluster as well as additional plants around Savannah, Georgia and in the mid-Atlantic regions, with capability to build and commission two plants per year, up from one per year Signed MOU with Enviva’s first U.S.-based customer, to develop a supply chain strategy to support the customer’s biofuel refining facilities in the Southeast U.S. and potentially California Announced

DXC Technology Expands Global Partnership with ServiceNow to Accelerate Enterprise Service Management and Operational Transformation, Underpinned by DXC Platform X™20.1.2022 00:00:00 EET | Press release

DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services company, announced the formation of a new global DXC ServiceNow Strategic Business Group to deliver market-leading, cost-efficient, resilient technology services that transform enterprise service operations, built on DXC Platform X TM. DXC has named ServiceNow the preferred workflow partner for DXC Platform X, a data-driven, intelligent automation platform that helps detect, prevent and address issues before they happen with resilient, self-healing IT estates. NelsonHall has named DXC Platform X as a “Leader in Cognitive & Self-Healing IT Infrastructure Management,” reflecting DXC’s ability to deliver immediate benefits through automation while meeting customer requirements for their future operating models. “For our customers, it’s about modernizing and automating their IT estates to achieve a state of ‘silent operations,’ saving time, money and letting customers focus on what’s most important --- running the

Dole Affiliate Receives Social Responsibility in Action Award in Costa Rica19.1.2022 20:57:00 EET | Press release

The American-Costa Rican Chamber of Commerce (AmCham) recognized Dole through its daughter company, Standard Fruit Company de Costa Rica S.A., with the Social Responsibility in Action Award in the Employees Category for their project "De la Mano con Dole" — which loosely translates to "Hand-in-Hand with Dole". This year marks the 25th anniversary of the award which was given December 8, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005875/en/ From left: Sandra Lima, Dole Corporate Social Responsibility Senior Manager; Steve Aronson, Horizonte Positivo Board Member; Ana Cristina Obregón, Dole Logistics & Planning Senior Director; Renato Acuña, President of Dole Fresh Fruit Latin America; Gisela Sánchez, AmCham Board President; and Marco Tulio Escobedo, Dole Human Resources Director (Photo: Business Wire) The Hand-in-Hand with Dole project is an initiative that works towards positively impacting the social develop

Q4 Inc. Announces Appointment of Julie Silcock, Investment Banking Veteran, to Board of Directors19.1.2022 20:48:00 EET | Press release

Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), a leading capital markets communications platform, today announced the appointment of Julie Silcock, currently a Senior Advisor at CDX Advisors, bringing 35 years of Capital Markets and M&A experience, to Q4’s Board of Directors, effective immediately. As a Senior Advisor at CDX Advisors, a tech-enabled investment bank, Ms. Silcock is involved in strategic advisory M&A and capital raising activities primarily for growth-oriented companies in the Southwest. Ms. Silcock previously served as Co-Head of Southwest Investment Banking at Houlihan Lokey and, prior to that, founded and acted as Head of Southwest Investment Banking at Citigroup. Ms. Silcock earned her M.B.A. from Stanford Graduate School of Business and holds a B.A. degree from Princeton University. She currently also serves on the boards of MoneyGram International, Overseas Shipholding Group, Inc., a crude oil and petroleum shipping company, JC Skincare, a privately held beauty compa

Alation Launches “Data Radicals” Podcast with Revolutionary Insights Transforming the Way We Use Data19.1.2022 17:00:00 EET | Press release

Alation Inc., the leader in enterprise data intelligence solutions, today announced the debut of its podcast, “Data Radicals.” Hosted by Satyen Sangani, CEO and co-founder of Alation, “Data Radicals” is a show for business, data, and technology enthusiasts who seek to enable individuals and organizations to use data in powerful ways. The podcast kicks off today, with the first 5 episodes available online, as well as Apple Podcasts, Spotify, and anywhere podcasts are available. “Data Radicals” is for anyone interested in how data, science, and technology can help solve the world’s most pressing problems. Episodes explore how data leaders and academics are driving data culture and the role they play in changing how people think and work. The podcast leaves listeners with an understanding of how to facilitate data-driven decision-making and data literacy at all levels of an organization. “The launch of ‘Data Radicals’ gives business leaders, entrepreneurs, and those of us passionate about

Protegrity Partners With Google Cloud to Support BigQuery Remote Functions19.1.2022 17:00:00 EET | Press release

Protegrity, a global leader in data security, today announced it has partnered with Google Cloud to support the upcoming release of BigQuery remote functions. First announced at Google Cloud Next ‘21 in October, BigQuery remote functions offer Google Cloud customers the ability to extend BigQuery with their own external code. With support for remote functions, Protegrity adds an additional layer of data protection, while enabling customers to deliver faster, more robust analysis through Google Cloud BigQuery. Protegrity’s partnership with Google Cloud lays a strong foundation to deliver de-identified data sets across many Google Cloud services. In addition to its support for Google Cloud remote functions, Protegrity also announced the availability of the Cloud API for Google Cloud, a serverless API that can be used to integrate data protection into cloud services and ETL workflows, as well as the Snowflake Protector on Google Cloud. “Through our partnership with Google Cloud, one of th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom